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INTRODUCTION
Glucocorticoids are the most effective therapy in
the long-term control of inflammatory and immune
reactions within the airway especially in bronchial
asthma (1). With the recognition that airway inflam-
mation is present even in patients with mild asth-
ma, therapy with inhaled corticosteroids is recom-
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mended at an earlier stage of the disease. For ex-
ample, the British Guidelines on Asthma Treat-
ment, published in 1995 (2), and the Guidelines
for the diagnosis and management of asthma, Ex-
pert Panel Report 2, published in 1997 by the Na-
tional Institute of Health, emphasize the role of in-
haled corticosteroids to obtain a long-term control
(3). Moreover, several studies indicated that regu-
lar use of inhaled corticosteroids would prevent the
major portion of asthma hospitalizations and deaths
(4-6).
In Japan, after the introduction of beclomethasone
dipropionate (BDP), an inhaled corticosteroid, to clini-
cal practice in 1978, the prescription of BDP is re-
ported to be increasing (7), and in addition, fluticasone
propionate (FP) was introduced as another inhaled
corticosteroid in 1998. Moreover, pranlukast, a
leukotriene receptor antagonist, was introduced to
clinical practice as early as 1995. In these situa-
tions, it is of interest to establish which drugs are
commonly used for the control of bronchial asthma
in a Japanese hospital and investigate the relation-
ship of the trend in drug use and therapeutic out-
come.
In the present study, we retrospectively examined
the prescriptions for inhaled corticosteroids and
other drugs for the treatment of outpatients with
bronchial asthma at Tokushima University Hospi-
tal. We also analyzed asthma control in these pa-
tients, in terms of the incidence of emergency con-
sultations and hospitalizations due to asthma exacer-
bations.
PATIENTS AND METHODS
Patients
We retrospectively examined the medical records
of outpatients with bronchial asthma who were treat-
ed regularly at asthma clinic at Tokushima Univer-
sity hospital. To analyze the recent trend, the pa-
tients observed from 1998 to 2000 were included,
and for control purpose, those from 1990 and 1991
were also included. The annual numbers of out-
patients with bronchial asthma are shown in Table
1.
Medications
The annual number of patients with prescriptions
for inhaled corticosteroids, oral corticosteroids, oral
xanthine derivatives, inhaled β2-adrenergic receptor
(β2-AR) agonists, oral β2-AR agonists, anti-leukotrienes
and other anti-allergic agents were established from
medical records. To further examine the prescription
of inhaled corticosteroids, those of beclomethasone
dipropionate (BDP : Becotide and Aldesin) and
fluticasone propionate (FP : Flutide) were defined.
Patients treated with each category of drugs are
shown as percentage of all outpatients.
Emergency consultations
In general, pulmonary physicians at outpatient
clinic follow patients with bronchial asthma regularly,
such as every two weeks and every four weeks. In
case of asthma exacerbations, patients are suggest-
ed to try inhaled β2-AR agonists or other drugs in-
dicated by the physician, and are also suggested
to consult outpatient clinic (emergency consultations),
if no relief was obtained by these treatment. Annual
numbers of emergency consultations are, therefore,
established to estimate asthma control. In addition,
incidence of emergency consultation per patient
(annual number of emergency consultation/ annual
number of total patients) was calculated.
Hospitalizations
The annual numbers of hospitalizations due to
asthma exacerbation were established from medi-
cal records to estimate asthma control. In addition,
incidence of hospitalization per patient (annual
number of hospitalization/ annual number of total
patients) was calculated.
Table 1. Annual nunbers of outpatients with bronchial asthma at Tokushima University Hospital
Annual numbers of outpatients with bronchial asthma
1990 1991 1998 1999 2000
Male
Female
42
50
60
86
62
132
100
127
59
104
Total 92 146 194 227 163
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RESULTS
Medications of corticosteroids
The annual percentage of patients treated with
inhaled corticosteroids and oral corticosteroids are
shown in Figure 1. As shown, the percentage of
patients treated with inhaled corticosteroids remark-
ably increased in 1998, 1999 and 2000 (71%, 87%
and 86%, respectively) compared to 1990 and 1991
(24% and 23% respectively). Among the inhaled
corticosteroids, increasing patients were treated
with fluticasone propionate after the introduction
of the drug in 1998. In contrast, the usage of oral
corticosteroids tended to decrease in 10 years pe-
riod.
Medications of xanthine derivatives and β 2-adrenergic
receptor agonists
The annual percentage of patients treated with
oral xanthine derivatives, inhaled β2-AR agonists,
oral β2-AR agonists, and inhaled anti-cholinergic
agents are shown in Figure 2. As shown, the usage
of these drugs, except inhaled anti-cholinergic agents,
tended to decrease in 10 years period. The usage
of inhaled anti-cholinergic agents remained stable
in 10 years.
Medications of anti-leukotrienes and other anti-allergic
agents
The annual number and percentage of patients
treated with anti-leukotrienes and other anti-allergic
agents are shown in Table 2. After the introduction
of anti-leukotrienes in 1995 in Japan, considerable
patients up to 25% were treated with anti-leukotrienes.
As shown, the usage of anti-allergic agents tended
to decrease in 10 years period.
Annual number and incidence of emergency con-
sultations
Annual numbers and incidences of emergency
consultations are shown in Figure 3. As shown,
emergency consultations remarkably decreased in
1998, 1999 and 2000 (0.15, 0.17 and 0.23 /patient/
year, respectively) compared to 1990 and 1991 (0.78
and 0.80/patient/year, respectively).
Annual number and incidence of hospitalizations
Annual numbers and incidences of hospitaliza-
Figure 1. Annual percentage of outpatients with bronchial asth-
ma treated with inhaled corticosteroids and oral corticosteroids
in years of 1990, 1991, 1998, 1999 and 2000.
Open bars, hatched bars and closed bars indicate inhaled
fluticasone propionate (FP) inhaled beclomethasone dipropionate
(BDP) and oral corticosteroids, respectively.
Table 2. Annual nunbers of outpatients with bronchial asthma treated with anti-leukotrienes and
other anti-allergic agents
Annual numbers (% of total outpatients)
Treatment 1990 1991 1998 1999 2000
Anti-leukotrienes
Anti-allergic agents
NA
51 (55.4)
NA
69 (47.3)
49 (25.5)
42 (21.9)
53 (23.3)
55 (19.1)
41 (25.2)
19 (11.7)
NA : not commercially available
Figure 2. Annual percentage of outpatients with bronchial
asthma treated with oral xanthine derivatives, inhaled β2-adrenergic
receptor (β2-AR) agonists, oral β2-AR agonists, and inhaled
anti-cholinergic agents in years of 1990, 1991, 1998, 1999 and
2000.
Open bars, hatched bars, dotted bars and closed bars indicate
oral xanthine derivatives, inhaled β2-adrenergic receptor (β2-AR)
agonists, oral β2-AR agonists, and inhaled anti-cholinergic agents,
respectively.
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tions are shown in Figure 4. As shown, hospitaliza-
tions remarkably decreased in 1998, 1999 and 2000
(0.05, 0.05 and 0.03 /patient/year, respectively)
compared to 1990 and 1991 (0.18 and 0.28/patient/
year, respectively).
DISCUSSION
Inhaled corticosteroid therapy was initially intro-
duced to reduce the need for oral corticosteroids
in patients with sever asthma (8). With the recog-
nition that airway inflammation is present even in
patients with mild asthma, inhaled corticosteroids
began to be used for patients with milder asthma
(1). In these circumstances, the usage of inhaled
corticosteroids is increasing all over the world. As
shown in Figure 1, the present study confirms the
widespread use of inhaled corticosteroids.
Various reports revealed that the addition of long
acting β2-AR agonist is more effective on the im-
provements in symptoms and lung function than
increasing dose of inhaled corticosteroids (9, 10).
At present, inhaled long acting β2-AR agonist is not
yet available in Japan. Instead, oral xanthine deriva-
tives, inhaled short-acting β2-AR agonists and oral
β2-AR agonists are used for the control of asthma
symptoms. Nevertheless, the present study revealed
that the usage of these agents was decreasing in
the 10 years period (Figure 2).
To estimate control of bronchial asthma, the risk
of hospitalizations has been examined in various
studies. In the study of 16941 children and adults
with bronchial asthma in Massachusetts from 1991
to 1994, Donahue et al. (4) reported that the over-
all relative risk of hospitalization among those who
received inhaled steroids was 0.5 and concluded that
inhaled steroids conferred significant protection
against exacerbations of asthma leading to hospi-
talizations. In the Saskatchewan study by Blais et al.
(5) from 1977 to 1993, among 13563 children and
adults with bronchial asthma, the first regular treat-
ment with inhaled corticosteroids initiated in the
year following the recognition of asthma could re-
duce the risk of admission to hospital for asthma
by up to 80% compared with regular treatment with
theophylline. The impact of inhaled corticosteroids
on asthma control was also reported by Eisner et al
(11) who examined life-threatening exacerbation in
terms of the risk of intensive care unit admission.
In addition, Suissa et al. (12) have recently reviewed
several studies and concluded that regular use of
inhaled corticosteroids would prevent the major por-
tion of asthma hospitalizations. In addition to the
risk of hospitalizations, we examined the incidence
of emergency consultations to estimate asthma con-
trol, since Japanese patients are suggested to con-
sult outpatient clinic in case of asthma exacerbations,
if no relief was obtained by relievers indicated by
the physicians at home first. As shown in Figures
3 and 4, lower incidence of emergency consultations,
as well as hospitalizations, was observed in years
of 1998, 1999 and 2000 than in years of 1990 and
1991.
Figure 3. Annual number (top) and incidence (bottom) of
emergency consultations due to asthma exacerbations in patients
with bronchial asthma in years of 1990, 1991, 1998, 1999 and
2000.
Figure 4. Annual number (top) and incidence (bottom) of
hospitalizations due to asthma exacerbations in patients with
bronchial asthma in years of 1990, 1991, 1998, 1999 and 2000.
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In inhaled steroid therapy, a substantial gap be-
tween recommendation and actual practice has of-
ten been pointed out (13). It is reported that only
about half of eligible patients with bronchial asth-
ma received inhaled steroid therapy (14). In the study
of elderly patients, forty percent of patients who
experienced a recent acute exacerbation of bron-
chial asthma did not receive inhaled steroid thera-
py near discharge from their initial hospitalization
for bronchial asthma (15). Further diffusion of in-
haled steroid therapy into clinical practice is neces-
sary, and more research must be conducted to ex-
amine the reason (s) for the barriers between rec-
ommendation and clinical practice.
Cysteinyl-leukotrienes are important pro-inflammatory
mediators in bronchial asthma and several studies
have already revealed clinical benefit of anti-leukotrienes
in bronchial asthma(16-20). Much attention has, there-
fore, been recently paid to the role of anti-leukotrienes
as a controller of bronchial asthma. As shown in
Table 2, considerable patients were treated with
anti-leukotrienes after the clinical introduction of
pranlukast to Japan in 1995. In comparative study
of inhaled corticosteroids and anti-leukotrienes, in-
haled corticosteroids had a larger clinical benefit
than anti-leukotrienes, although anti-leukotrienes
seemed to have superior effects in certain group of
patients (21-23). Therefore, it seems to be difficult
to consider anti-leukotrienes as a major contributor
of the better control of bronchial asthma in years
of 1998, 1999 and 2000 in the present study. Further
studies are warranted to establish the impact of
anti-leukotrienes to reduce the risk of exacerbations
in bronchial asthma.
In conclusion, spread of inhaled steroid therapy
and decline in incidence of emergency consultation
and hospitalization were simultaneously observed
at Tokushima University Hospital, and the former
has, at least in part, a contribution to the latter.
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